- NASDAQ: INO is set to extend its fall for the fourth day in a row.
- The FDA's upcoming approval of the Pfizer/BioNTech COVID-19 vaccine shows Inovio is behind.
- Bargain-seekers may want to examine Inovio Pharmaceuticals' other products.
Can a small firm compete with Big Pharma? That has always been the question for Inovio Pharmaceuticals Inc (NASDAQ: INO) – and in recent days the answer seems to be negative. Investors are selling the stock in the past three days, and Thursday will likely be a down day as well.
The Plymouth Meeting, Pennsylvania-based company is working on a COVID-19 vaccine but ran into bumps along its way. The Food and Drugs Administration (FDA) demanded clarifications from Inovio about its administering the immunization using the Cellectra 2000 device. That has delayed the full rollout of the company's INNOVATE Phase 3 trial of the INO-4800 vaccine candidate.
One of the reasons for the most recent decline comes from the FDA as well, and also correlated to coronavirus – the highly-regarded regulator is set to approve the Pfizer/BioNTech jab, following a successful Phase 3 trial. Moderna's jab will likely receive the green light next week.
Has Inovio lost the race? Not so fast.
Inovio Pharmaceuticals Stock
Inovcio Pharmaceutical's shares are changing hands at $11.25 in premarket trading, down another 1.57% after slipping 4.35% on Wednesday. They are down over 10% from the closing price of $12.60 on Friday but still above the late November trough of $10.15. The coronavirus-dominated year has been turbulent for INO's stock, which ranged from a low of $2.42 to $33.79 in the past 52 weeks.
NASDAQ: INO still has room to run, including on a covid vaccine. Doses can survive a full month at 37 Celsius. Pfizer's material has weak thermostability, expiring after five days in room temperature – after coming out of extremely cold -80C storage conditions.
While Moderna's thermal profile is better, it still requires cooling and a regular injection, something that Inovio's vaccine bypasses by using the special Cellectra 2000 device.
Moreover, NASDAQ: INO's recent decline may provide a buying opportunity for those seeking a longer-term investment. It is essential to note that the company run by CEO: J. Joseph Kim is focused on the promising genetic field to develop treatments for cancer and infectious diseases – not only COVID-19.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD stays near 1.0400 in thin holiday trading
EUR/USD trades with mild losses near 1.0400 on Tuesday. The expectation that the US Federal Reserve will deliver fewer rate cuts in 2025 provides some support for the US Dollar. Trading volumes are likely to remain low heading into the Christmas break.
GBP/USD struggles to find direction, holds steady near 1.2550
GBP/USD consolidates in a range at around 1.2550 on Tuesday after closing in negative territory on Monday. The US Dollar preserves its strength and makes it difficult for the pair to gain traction as trading conditions thin out on Christmas Eve.
Gold holds above $2,600, bulls non-committed on hawkish Fed outlook
Gold trades in a narrow channel above $2,600 on Tuesday, albeit lacking strong follow-through buying. Geopolitical tensions and trade war fears lend support to the safe-haven XAU/USD, while the Fed’s hawkish shift acts as a tailwind for the USD and caps the precious metal.
IRS says crypto staking should be taxed in response to lawsuit
In a filing on Monday, the US International Revenue Service stated that the rewards gotten from staking cryptocurrencies should be taxed, responding to a lawsuit from couple Joshua and Jessica Jarrett.
2025 outlook: What is next for developed economies and currencies?
As the door closes in 2024, and while the year feels like it has passed in the blink of an eye, a lot has happened. If I had to summarise it all in four words, it would be: ‘a year of surprises’.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.